Cingulate
Kansas City, Kansas, United States · Biopharma, Biotechnology, Healthcare
Cingulate® is a biopharmaceutical company utilizing its innovative Precision Timed Release™ (PTR) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products. We aim to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an
Key facts
- Headquarters
- Kansas City, Kansas, United States
- Employees
- 22
- Industries
- Biopharma, Biotechnology, Healthcare
- Status
- Public (CING)
- Website
- cingulate.com
- Company page
Recent activity at Cingulate
- : SEC 8-K (5.02): On September 30, 2026, Cingulate Therapeutics LLC, a wholly owned subsidiary of Cingulate Inc., entered into amendment No. 2 to the Employment Agreement with Matthew N. Brams, who serves as the Executive Vice President and Chief Medical Officer. This amendment is effective as of January 1, 2026, and may include adjustments to his compensatory arrangements. The strategic implications might involve changes in leadership dynamics or shifts in the direction of medical strategy within the company, although specific financial details related to the amendments have not been disclosed. As this event occurred within the past 3 days, it is categorized under Item 5.02 concerning changes in officers.
- : SEC 8-K (5.02):
- : SEC 8-K (5.02):
- : SEC 8-K (5.02): On June 30, 2026, Cingulate Therapeutics LLC (a subsidiary of Cingulate Inc.) entered into an amendment to the employment agreement with Matthew N. Brams, who serves as the Executive Vice President and Chief Medical Officer. The amendment extends Mr. Brams' trial period of full-time employment from June 30, 2026, to September 30, 2026. This change reflects the company's strategic decision to retain experienced leadership as they navigate upcoming initiatives.
- : SEC 8-K (7.01): On June 16, 2026, Cingulate Inc. announced the issuance of U.S. Patent No. 12,653,791 by the United States Patent and Trademark Office, which covers critical aspects of the formulation and method of use for CTx-1301 until December 2042. This patent follows a previous Notice of Allowance, signifying a significant advancement for the Company's intellectual property portfolio and potentially enhancing its market position for CTx-1301. The announcement emphasizes the strategic importance of this patent in protecting the Company's innovative therapies, providing a competitive edge in the pharmaceutical market.
- : SEC 8-K (8.01): On June 2, 2026, Cingulate Inc. announced that the FDA issued a Complete Response Letter (CRL) regarding its New Drug Application for CTx-1301. The CRL highlighted specific Chemistry, Manufacturing and Controls information requests but did not raise current concerns about clinical safety or efficacy. The company plans to promptly resubmit the required information to address the issues raised. This development can significantly impact Cingulate's timeline for bringing CTx-1301 to market and may influence investor perceptions and stock performance.
- : SEC 8-K (5.02): On May 18, 2026, Cingulate Inc. announced changes within its Board of Directors. Current directors Jeff Ervin and Jay Roberts will not seek re-election at the Company's upcoming 2026 Annual Meeting, which aims to reduce the Board's size to five members. Jeff Hargroves resigned from his position as a Class I director to be re-appointed as a Class II director immediately after his resignation. This strategic move helps align the Board's composition with the company's governance provisions, and Hargroves has been nominated to stand for election during the Annual Meeting.
- : SEC 8-K (5.02):
- : SEC 8-K (1.01): On March 24, 2026, Cingulate Inc. entered into an ATM Sales Agreement with A.G.P./Alliance Global Partners, allowing the Company to offer and sell shares of its common stock for aggregate gross proceeds of up to $100,000,000. The placement will be conducted through 'at-the-market' equity offerings on the Nasdaq Capital Market, where A.G.P. will act as the sales agent. A commission of 3.0% of the gross proceeds will be paid to A.G.P., along with customary indemnification rights. The agreement can be suspended or terminated at the Company's discretion, creating strategic financial flexibility.
- : SEC 8-K (8.01): On March 17, 2026, the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for Cingulate Inc.'s patent application related to its lead asset CTx-1301, an innovative treatment for Attention Deficit Hyperactivity Disorder (ADHD). This patent, once granted, will provide protection for the formulation until May 2042, significantly enhancing the company's competitive position and potential market exclusivity. The patent's approval is expected to bolster the company's strategic initiatives in the ADHD treatment market, providing opportunities for further research and development. This filing details the acceptance of a pivotal patent that could lead to substantial financial implications for Cingulate Inc. in the coming years.
Cingulate funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2021 | Venture | Undisclosed |
Leadership
- Gregg Givens, Director
- Curt Medeiros, Director
- Shane Schaffer, Executive Officer, Director
- Patrick Gallagher, Director
- Jeff Hargroves, Director
- Peter Werth, Director
- Jeff Conroy, Director
- Matthew N. Brams, Chief Medical Officer
- Nilay Patel, Chief Legal Officer
- Jennifer Callahan, Chief Financial Officer
Verified email and direct lines for Cingulate’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Cingulate in the news
- FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301 - The American Journal of Managed Care (Jun 03, 2026)
- FDA Issues CRL for CTx-1301 for Treatment of ADHD - Psychiatric Times (Jun 02, 2026)
- Cholecystokinin input from the anterior cingulate cortex to the lateral periaqueductal gray mediates nocebo pain behavior in mice - Nature (May 20, 2026)
- Cingulate Receives Complete Response Letter from FDA for CTx-1301 - GlobeNewswire (Jun 02, 2026)
- Anterior cingulate neurons combine outcome monitoring of past decisions with ongoing movement signals - Nature (Mar 24, 2026)
- Shane Schaffer, Cingulate Chairman & CEO to Present “SMART - GlobeNewswire (Sep 17, 2026)
- FDA Issues Complete Response Letter for Cingulate ADHD Drug CTx-1301 - Patient Care Online (Jun 02, 2026)
- Cingulate reports phase 3 safety data for CTx-1301 to treat ADHD in children, adolescents - Contemporary Pediatrics (Mar 04, 2025)
Companies similar to Cingulate
- Os Therapies · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical
- Lipella Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical
- Galmed Pharmaceuticals Ltd · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical
- Reneo Pharmaceuticals, Inc. · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical
- Arbutus · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical
About Cingulate: questions and answers
What does Cingulate do?
Cingulate® is a biopharmaceutical company utilizing its innovative Precision Timed Release™ (PTR) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products. We aim to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an
Where is Cingulate headquartered?
Cingulate is headquartered in Kansas City, Kansas, United States.
How many employees does Cingulate have?
Cingulate has about 22 employees.
Has Cingulate raised funding?
Yes. Fundz has recorded 1 funding event for Cingulate. The most recent, Undisclosed, was in Sep 2021.
What is the latest news on Cingulate?
On Sep 30, 2026, SEC 8-K (5.02): On September 30, 2026, Cingulate Therapeutics LLC, a wholly owned subsidiary of Cingulate Inc., entered into amendment No. 2 to the Employment Agreement with Matthew N. Brams, who serves as the Executive Vice President and Chief Medical Officer. This amendment is effective as of Janu
Is Cingulate a public company?
Yes. Cingulate is publicly traded under the ticker CING.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy